Dogwood Therapeutics, Inc. DWTX
Set alert
At close
Pre-market · Nov 2, 3:36 AM ET
- YTD
- -69.23%
- 1 year
- -80.75%
- Open
- 1.30
- Prev close
- 1.23
- Mkt cap
- 48.93M
- Vol
- 62.22K
- Avg vol
- 69.91K
- EPS
- 2.20
- P/E
- 0.58
- Div yield
- 0.00%
More statistics
- Low
- 1.28
- High
- 1.36
- Forward P/E
- -0.43
- Beta
- 0.00
- Short ratio
- 0.42
- Inst. own
- 3.24%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.32
- 200-d avg
- 6.07
- 1y target
- 13.83
1M chart
Signals (7)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
Key statistics
- Market cap
- 3.62M
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- -0.43
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.55
- EPS (TTM)
- -6.32
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 1.33M
- Short % of float
- 2.56%
- 50-day average
- 3.32
- 200-day average
- 6.07
Analyst view
Consensus: none
- Target (low)
- 5.00
- Target (mean)
- 13.83
- Target (high)
- 25.00
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.33 | -2.05 | -0.72 | -54.14% |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dwtx.com
News
Your note
Sign in to keep a note on DWTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUNCAN GREGORY SCOTT | Chief Executive Officer | Purchase | Aug 16, 2023 | 57,461 |
| PRIDGEN WILLIAM L | Director | Purchase | Aug 20, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 1.39% | 18,460 | 50.21K | Sep 29, 2024 |
| Vanguard Group Inc | 1.25% | 16,711 | 45.45K | Sep 29, 2024 |
| UBS Group AG | 1.12% | 14,885 | 40.49K | Sep 29, 2024 |
| HRT Financial LP | 0.49% | 6,526 | 17.75K | Sep 29, 2024 |
| State Street Corporation | 0.32% | 4,226 | 11.49K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.32% | 4,271 | 11.62K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.25% | 16,711 | 45.45K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 5,942 | 16.16K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 2,294 | 6.24K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 1,750 | 4.76K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 880 | 2.39K | Oct 30, 2024 |